LashayFmm33111: added a post...

2026-02-18T09:04:21Z

added a post...

New page

{{Short description|Indian multinational pharmaceutical company}}
{{distinguish|Cadila Pharmaceuticals}}
{{Use dmy dates|date=August 2018}}
{{Use Indian English|date=August 2018}}
{{Infobox company
| name = Zydus Lifesciences Limited
| image = Zydus Lifesciences.svg
| type = [[Public company|Public]]
| traded_as = {{ubl|{{BSE|532321}}|{{NSE|ZYDUSLIFE}}}}
| founder = [[Ramanbhai Patel]]
| key_people = [[Pankaj Patel|Pankaj R. Patel]]<br />{{small|(Chairman)}}<br />Sharvil P. Patel<br />{{small|(Managing Director)}}
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = {{hlist|[[Pharmaceutical]]s |[[generic drug]]s |[[over-the-counter drug]]s |[[vaccine]]s |[[Medical diagnosis|diagnostics]] |[[contact lens]]es |[[Veterinary medicine|animal health]] }}
| revenue = {{up}} {{INRConvert|23241|c}} (2025)
| operating_income = {{up}} {{INRConvert|7058|c}} (2025)
| net_income = {{up}} {{INRConvert|4745|c}} (2025)
| num_employees = 25,000+ (2023)
| foundation = {{Start date and age|1952|p=y}}
| location = [[Ahmedabad]], [[Gujarat]], India
| subsid = [[Zydus Wellness]] (57.59%)<ref>{{cite news |title=Cadila Healthcare Limited |url=https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/CadilaHealthcareLimited_November%2030,%202021_RR_281821.html |access-date=31 January 2023 |work=CRISIL}}</ref>
| homepage = {{URL|http://www.zyduslife.com/}}
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Earnings Presentation: Q4 & Full Year FY25 |url=https://zyduslife.com/investor/admin/uploads/15/85/May-2025.pdf |publisher=Zydus Lifesciences Limited |access-date=28 May 2025}}</ref>
}}

'''Zydus Lifesciences Limited''', formerly known as '''Cadila Healthcare Limited''',<ref>{{cite news |last1=Umarji |first1=Vinay |title=Cadila Healthcare changes name to Zydus Lifesciences Limited |url=https://www.business-standard.com/article/companies/cadila-healthcare-changes-name-to-zydus-lifesciences-limited-122022401005_1.html |access-date=17 March 2022 |work=Business Standard India |date=24 February 2022}}</ref> is an Indian multinational [[pharmaceutical]] company headquartered in [[Ahmedabad]]. Primarily engaged in the manufacturing of [[generic drugs]],<ref name="The Hindu Business Line">{{Cite news|url=http://www.thehindubusinessline.com/companies/announcements/others/zydus-launches-sovihep-the-breakthrough-therapy-for-hepatitis-c-in-alliance-with-gilead-sciences/article7003039.ece|title=Zydus launches SoviHep - the breakthrough therapy for Hepatitis C in alliance with Gilead Sciences|date=2015-03-17|work=The Hindu Business Line|access-date=2017-12-29|language=en}}</ref><ref name="mapsofindia">{{cite web|date=21 June 2011|title=A Complete Overview on Cadila Healthcare, a growing and popular company in India.|url=http://business.mapsofindia.com/sectors/manufacturing/cadila-healthcare.html|access-date=2009-02-04|website=business.mapsofindia.com}}</ref><ref>{{Cite web|title=Cadila Healthcare Profit and Loss Reports – The Economic Times|url=https://economictimes.indiatimes.com/cadila-healthcare-ltd/profitandlose/companyid-3778.cms|access-date=2020-06-15|website=economictimes.indiatimes.com}}</ref> the company ranked 100th in the [[Fortune India 500|''Fortune'' India 500]] list in 2020.<ref>{{Cite web|title=Cadila Healthcare – Fortune 500 List 2020 – Fortune India|url=https://www.fortuneindia.com/fortune-500/company-list/cadila-healthcare?year=2020|access-date=2021-01-12|website=fortuneindia.com|language=en}}</ref>

== History ==
Cadila was founded in 1952 by [[Ramanbhai Patel]] (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner [[Indravadan Modi]].<ref>{{cite news |title=India's Richest 2019: Cadila's Patels' Quest For The Magic Pill |url=https://www.forbesindia.com/article/india-rich-list-2019/india039s-richest-2019-cadila039s-patels039-quest-for-the-magic-pill/56171/1 |access-date=2 October 2023 |work=Forbes India |language=en}}</ref>

In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called [[Cadila Pharmaceuticals]], and Cadila Healthcare became the Patel family's holding company. Cadila Healthcare had its [[initial public offering]] in February 2000 and listed on the [[Bombay Stock Exchange|BSE]].<ref>{{cite news |title=Cadila shares close IPO price after 3 years |url=https://timesofindia.indiatimes.com/business/india-business/cadila-shares-close-ipo-price-after-3-years/articleshow/101727.cms |access-date=2 October 2023 |work=The Times of India |date=29 July 2003}}</ref>

In 2003, the company [[Mergers and acquisitions|merged]] another Indian pharmaceutical company called German Remedies into itself.<ref>{{cite news |title=German Remedies to be merged with Cadilla |url=https://timesofindia.indiatimes.com/business/india-business/german-remedies-to-be-merged-with-cadilla/articleshow/122464.cms |access-date=2 October 2023 |work=The Times of India |date=9 August 2003}}</ref> On 25 June 2007, the company acquired Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) as part of Zydus Healthcare Brasil Ltda.<ref>[https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=35196980 Company Overview of Química e Farmacêutica Nikkho do Brasil Ltda] ''Bloomberg''</ref>

In 2014, Cadila Healthcare launched the world's first ''[[adalimumab biosimilar]]'' under the brand name Exemptia at one-fifth the originator's price.<ref>[https://web.archive.org/web/20150328064218/http://articles.economictimes.indiatimes.com/2014-12-09/news/56879703_1_rheumatoid-arthritis-first-biosimilar-humira Zydus Cadila launches biosimilar of AbbVie's Humira in India] ''The Economic Times'' 9 December 2014</ref>
Zydus Cadila Healthcare has also launched its first research based drug molecule [[Saroglitazar]] in the treatment of Diabetic Dyslipidemia under brand name "Lipaglyn". SoviHep is the first [[sofosbuvir]] brand launched in India by Zydus in the year 2015.<ref name="The Hindu Business Line"/>

In 2019, injectable [[ketorolac]] tromethamine manufactured by Zydus (Cadila Healthcare) was recalled due to microbial growth.<ref>{{cite news |title=Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance |url=https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sagent-pharmaceuticals-issues-voluntary-nationwide-recall-ketorolac-tromethamine-injection-usp |access-date=2 October 2023 |work=FDA |date=29 September 2020 |language=en}}</ref>

In 2020, Zydus Cadila's drug Desidustat received approval by the [[Food and Drug Administration|USFDA]] to initiate clinical trials on [[cancer]] patients.<ref>[https://timesofindia.indiatimes.com/india/zydus-cadila-gets-usfda-nod-for-drug-trials-to-treat-chemotherapy-induced-anemia/articleshow/77121315.cms Zydus Cadila Desidustat Gets USFDA Nod To Initiate Clinical Trials On Cancer Patients] ''The Times Of India'' 23 July 2020</ref>

In 2022, Cadila Healthcare Ltd was renamed as Zydus Lifesciences Ltd.<ref>{{cite news |title=Cadila Healthcare changes name to Zydus Lifesciences Limited |url=https://www.business-standard.com/article/companies/cadila-healthcare-changes-name-to-zydus-lifesciences-limited-122022401005_1.html |access-date=2 October 2023 |work=Business Standard}}</ref>

In October 2024, USFDA Approval for Prostate Cancer Drug: Zydus Lifesciences received USFDA approval to manufacture [[enzalutamide]] tablets, which are used for treating [[prostate cancer]]. This drug, an androgen receptor inhibitor, is designed for patients with castration-resistant and metastatic castration-sensitive prostate cancer. The product will be manufactured at Zydus' facility in Ahmedabad. This approval is part of the company's broader efforts to expand its portfolio of cancer treatments in the U.S. market.

In 2025, Zydus acquired the CDMO business of [[Agenus]] including their two biologics manufacturing sites in Emeryville and Berkeley. In addition, they would partner with Agenus to commercialize their molecules in India.<ref>{{cite news |title=Agenus signs agreements for botensilimab and balstilimab |url=https://www.pharmaceutical-technology.com/news/agenus-agreements-botensilimab-balstilimab/?cf-view |work=Pharmaceutical Technology |date=4 June 2025}}</ref>

=== Acquisition history ===
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

{{Tree list}}
* '''Zydus Lifescience'''
** Cadila Healthcare {{small|(Split from Cadila 1995)}}
** German Remedies {{small|(Acq 2003)}}
** Química e Farmacêutica Nikkho do Brasil Ltda (Nikkho) {{small|(Acq 2007)}}
** [[Agenus]] {{small|(Acq 2025)}}
{{tree list/end}}

== Products ==
From twenty-five pharmaceutical production operations in India and Zydus Cadila develops and manufactures an extensive range of pharmaceuticals as well as diagnostics, [[Herbal medicine|herbal]] products, skincare products and other OTC products. Starting from late 2015, having concluded a voluntary license agreement with [[Gilead Sciences|Gilead]], the company also produces the generics for [[hepatitis C]] treatment (i.e. [[sofosbuvir]], distributed under the brand name SoviHep).<ref>{{cite web|url=http://hep-c-news.com/hepatitis-c-treatment-in-india-for-less-than-1000/|title=Hepatitis C treatment in India for less than $1000|date=11 July 2016|website=hep-c-news.com|publisher=Hep C News|archive-url=https://web.archive.org/web/20160916124038/http://hep-c-news.com/blog/2016/07/11/hepatitis-c-treatment-in-india-for-less-than-1000/|archive-date=16 September 2016|url-status=dead}}</ref>

The company makes [[active pharmaceutical ingredient]]s at three sites in India, [[Ankleshwar]] plants, [[Vadodara]] plant, and [[Patalganga]] plant.

==COVID-19 vaccine development==
[[File:The Prime Minister, Shri Narendra Modi visits the Zydus Biotech Park, in Ahmedabad, Gujarat on November 28, 2020 (7).jpg|thumb|Prime Minister [[Narendra Modi]] during his visit to the Zydus Biotech Park in Ahmedabad in 2020.]]
In July 2020, the company got permission to conduct human trials of the developmental [[COVID-19 vaccine]] named [[ZyCoV-D]], from the [[Drugs Controller General of India]] (DCGI), [[Government of India]].<ref>{{cite news |title=Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials |url=https://www.thehindu.com/sci-tech/health/potential-covid-19-vaccine-by-zydus-cadila-gets-dcgi-nod-for-human-clinical-trials/article31977556.ece |work=The Hindu |date=3 July 2020 |language=en-IN}}</ref><ref>{{cite news |title=Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld |url=https://health.economictimes.indiatimes.com/news/pharma/zydus-cadila-begins-human-clinical-trials-of-covid-19-vaccine-candidate/76975377 |work=ETHealthworld.com |language=en}}</ref><ref>{{cite news |title=Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial |url=https://www.nytimes.com/reuters/2020/08/05/world/asia/05reuters-health-coronavirus-zydus-vaccine.html |work=The New York Times |date=5 August 2020}}</ref> On 20 August 2021, DCGI granted emergency use approval of ZyCoV-D.<ref>{{cite news |title=India gives emergency approval for world's first COVID-19 DNA vaccine |url=https://www.reuters.com/business/healthcare-pharmaceuticals/india-approves-zydus-cadilas-covid-19-vaccine-emergency-use-2021-08-20/ |work=Reuters |date=20 August 2021 }}</ref>

Cadila is also among the several Indian pharma companies that received the licensing agreements from the [[Gilead Sciences]] to produce ''[[remdesivir]]''.<ref>{{cite news |last1=Umarji |first1=Vinay |title=Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila |url=https://www.business-standard.com/article/companies/gilead-finds-fourth-partner-for-manufacture-of-remdesivir-in-zydus-cadila-120061201687_1.html |work=Business Standard India |date=12 June 2020}}</ref>

== Corporate control ==
Zydus Cadila's major shareholder remains the Patel family. [[Pankaj Patel]] (born 1953), son of the founder, is the chairman of the company. In 2004, Pankaj Patel was included in ''[[Forbes|Forbes'<nowiki/>]]'' annual list of India's richest people. As of 2020, ''Forbes'' estimates Patel's net worth at US$3.9 billion, making him India's 46th richest person.<ref>{{Cite web|title=Pankaj Patel|url=https://www.forbes.com/profile/pankaj-patel/|access-date=2020-06-15|website=Forbes}}</ref>

== Controversies ==
A ''[[Mint (newspaper)|Mint]]'' investigative report in 2021 claimed that Zydus Lifesciences supplied possibly bacteria-contaminated batches of [[remdesivir]] to hospitals in [[Uttar Pradesh]], [[Rajasthan]], [[Maharashtra]], [[Gujarat]] and [[Bihar]], allegedly making hundreds of already sick COVID-19 patients even sicker.{{medical citation needed|date=May 2024}} Zydus was manufacturing the remdesivir in their Gujarat factory under license from United States' [[Gilead Sciences]]. In May 2021, when state procurement agency Rajasthan Medical Services Corporation sought an explanation, Zydus stated that they had not seen similar adverse reactions to their remdesivir elsewhere and denied all contamination allegations.<ref>{{Cite web |date=2021-12-23 |title=The dangerous failure to stop tainted remdesivir |url=https://www.livemint.com/science/health/the-dangerous-failure-to-stop-tainted-remdesivir-11640197634967.html |access-date=2023-08-01 |website=mint |language=en}}</ref>{{Primary source inline|dat=May 2024|date=May 2024}}

In December 2016, Zydus Discovery DMCC, a research subsidiary Zydus Lifesciences, was cited by the [[Food and Drug Administration | US FDA]] for deliberately misbranding their flagship product, [[Saroglitazar]]—the drug used to treat diabetic dyslipidemia in India. In a 21 December 2016 letter to the company, the US FDA asked it to stop using broad statements, such as the "world's first" and to stop suggesting that the drug is approved throughout the world, including in the United States, when that is not true.<ref>{{Cite news |last=Dandekar |first=Vikas |date=2016-12-28 |title=Cadila Healthcare misbranded Saroglitazar, says US FDA |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cadila-healthcare-misbranded-saroglitazar-says-us-fda/articleshow/56214730.cms |access-date=2023-08-01 |issn=0013-0389}}
</ref>

== See also ==
* [[Pharmaceutical industry in India]]

== References ==
{{Reflist}}

==External links==
* {{Official website|https://www.zyduslife.com/}}

{{Nifty 200 companies}}

{{Authority control}}

[[Category:Pharmaceutical industry in Gujarat]]
[[Category:Pharmaceutical companies of Gujarat]]
[[Category:Manufacturing companies based in Ahmedabad]]
[[Category:Health care companies of India]]
[[Category:Pharmaceutical companies established in 1952]]
[[Category:1952 establishments in Bombay State]]
[[Category:Indian companies established in 1952]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:COVID-19 vaccine producers]]
[[Category:Multinational companies headquartered in India]]

Zydus Lifesciences - Revision history

LashayFmm33111: added a post...